| Literature DB >> 35501859 |
Lilian Bao1,2, Lei Cheng2, Xiufang Gao2, Fangying Yan2, Huihua Fan2, Ying Shan2, Yong Li2, Haiming Shi2, Guoqian Huang2, Liwen Bao3.
Abstract
BACKGROUND: Three dimensional speckle tracking echocardiography (3D STE) is a novel technique combining 3D echocardiography and speckle tracking analysis. 3D STE software dedicated to the left atrium (LA) was recently available. Our study aimed to assess (1) atrial fibrillation (AF) related LA morpho-functional remodeling using 3D STE and (2) value of LA function parameters in identifying paroxysmal AF (PAF).Entities:
Keywords: Atrial fibrillation; Left atrial function; Left atrial strain; Remodeling; Three dimensional speckle tracking echocardiography
Mesh:
Year: 2022 PMID: 35501859 PMCID: PMC9061228 DOI: 10.1186/s12947-022-00282-5
Source DB: PubMed Journal: Cardiovasc Ultrasound ISSN: 1476-7120 Impact factor: 2.263
Fig. 1An example of motion tracking analysis of LA using 4D Auto LAQ, Echopac, GE Health. A Display of acquired LA 3D images showing apical four-chamber, two-chamber, three-chamber plane on the left and 9 slices of short-axis views from mitral annular plane to the atrial roof. B Landmark setting stage with three landmarks set at proper places according to the instruction. C Review stage with the LA endocardial contour traced. D A simulated model of reconstructed LA and output parameters. E LA strain/volume-time curve
Fig. 2An example of the (longitudinal/circumferential) LA strain-time curve. ED = end ventricular diastole, ES = end ventricular systole, PreA = pre atrial contraction
Baseline characteristics among three groups
| Variables | Control | PAF | Per-AF | |
|---|---|---|---|---|
| Age | 60 (60,69) | 68 (61,73) | 69 (64,75)* | 0.001 |
| Male | 36 (61%) | 87 (63%) | 73 (67%) | 0.576 |
| Height(cm) | 164 (160,172) | 167 (160,173) | 168 (160,174) | 0.448 |
| Weight(kg) | 66 ± 10 | 68 ± 11 | 69 ± 11 | 0.212 |
| BMI(kg/m2) | 24.1 ± 3.0 | 24.6 ± 3.1 | 24.8 ± 3.4 | 0.378 |
| BSA(m2) | 1.73 ± 0.16 | 1.76 ± 0.17 | 1.77 ± 0.19 | 0.263 |
| SBP(mmHg) | 130 (120,139) | 133 (122,143) | 132 (120,142) | 0.105 |
| DBP(mmHg) | 81 (75,86) | 80 (74,85) | 80 (75,89) | 0.583 |
| HR(bpm) | 69 (63,76) | 67 (60,73) | 77 (64,91)*† | < 0.001 |
| Comorbidity | ||||
| CHF | 0 | 4 (2.9%) | 17 (15.6%)*† | < 0.001 |
| Hypertension | 13 (22%) | 84 (60%)* | 76 (70%)* | < 0.001 |
| T2DM | 4 (7%) | 22 (16%) | 30 (27%)* | 0.002 |
| CAD | 0 | 24 (17%)* | 36 (33%)*† | < 0.001 |
| Stroke | 0 | 17 (12%)* | 34 (31%)*† | < 0.001 |
| PVD | 0 | 2 (1%) | 4 (2%) | 0.411 |
| AF duration (month) | / | 24 (2,60) | 48 (5,91) | 0.016 |
| CHA2DS2-VASc | / | 2 (1,4) | 3 (2,5) | < 0.001 |
| NT pro-BNP | / | 120 (39,444) | 956 (520,1918) | < 0.001 |
| Antiarrhythmic medication | ||||
| Type I | / | 32 (23%) | 4 (4%) | < 0.001 |
| Type II | / | 52 (37%) | 43 (39%) | 0.743 |
| Type III | / | 35 (25%) | 7 (6%) | < 0.001 |
| Anticoagulant therapy | / | 66 (47%) | 46 (42%) | 0.407 |
| Ablation | / | 17 (13%) | 5 (5%) | 0.029 |
BMI Body mass index, BSA Body surface area, SBP Systolic blood pressure, DBP Diastolic blood pressure, HR Heart rate, CHF Congestive heart failure, T2DM Type 2 diabetic mellitus, CAD Coronary artery disease, PVD Peripheral vascular disease, NT pro-BNP N terminal pro B type natriuretic peptide
*p after Bonferroni’s correction < 0.05 versus control group
†p after Bonferroni’s correction < 0.05 versus PAF group
Conventional TTE results among three groups
| Parameters | Control | PAF | Per-AF | |
|---|---|---|---|---|
| LVEDD(mm) | 48 (45,52) | 49 (46,52) | 48 (45,52) | 0.608 |
| LVEDV(ml) | 64 (55,82) | 72 (57,84) | 65 (52,80) | 0.118 |
| LVESV(ml) | 22 (18,30) | 27 (20,32) | 29 (22,36)* | 0.001 |
| LVEF(%) | 64 (60,67) | 62 (58,67) | 54 (48,61)*† | <0.001 |
| E(cm/sec) | 66 (57,76) | 70 (58,83) | 95 (83,107)*† | <0.001 |
| A(cm/sec) | 86 (75,98) | 78 (65,93)* | / | 0.007 |
| E/A | 0.77 (0.69,0.86) | 0.88 (0.70,1.12)* | / | 0.002 |
| Septal e’(cm/sec) | 6 (6,8) | 6 (5,8) | 9 (7,10)*† | <0.001 |
| Lateral e’(cm/sec) | 9 (7,11) | 9 (7,10) | 12 (10,14)*† | <0.001 |
| Septal a’(cm/sec) | 9 (9,10) | 9 (8,10) | / | 0.264 |
| Lateral a’(cm/sec) | 11 (10,14) | 11 (8,12)* | / | 0.011 |
| E/e’ | 8.3 (7.1,9.6) | 9.3 (7.5,11.0)* | 9.4 (7.1,11.4)* | 0.026 |
| TRMax(m/s) | 2.31 (2.12,2.57) | 2.47 (2.27,2.76) | 2.48 (2.27,2.78)* | 0.038 |
| LVDF grade | * | *† | <0.001 | |
| Normal | 56 (95%) | 104 (75%) | 58 (56%) | |
| Indeterminate | 2 (3%) | 20 (14%) | / | |
| Diastolic dysfunction | 1 (2%) | 15 (11%) | 45 (74%) | |
| AP-LAD(mm) | 35 (33,38) | 39 (36,41)* | 45 (42,47)*† | <0.001 |
| SI-LAD(mm) | 47 (44,52) | 51 (47,55)* | 60 (54,66)*† | <0.001 |
| ML-LAD(mm) | 34 (31,39) | 38 (34,41)* | 43 (39,47)*† | <0.001 |
| 2DLAVImax (ml/m2) | 22 (18,26) | 27 (21,31)* | 42 (31,51)*† | <0.001 |
LVEDD Left ventricular end-diastolic diameter, LVEDV Left ventricular end-diastolic volume, LVESV Left ventricular end-systolic volume, LVEF Left ventricular ejection fraction measured by Biplane Simpson method, E Early filling velocity of trans-mitral Doppler flow, A Late filling velocity of trans-mitral Doppler flow, E/A E to A ratio, Septal e’ Peak early diastolic mitral annular velocity at septal wall, Lateral e’ Peak early diastolic mitral annular velocity at lateral wall, Septal a’ Peak late diastolic mitral annular velocity at septal wall, Lateral a’ Peak late diastolic mitral annular velocity at lateral wall, E/e’ E to e’ ratio (e’ being the average value of septal e’ and lateral e’), TRMax Maximal tricuspid regurgitation velocity, LVDF grade Left ventricular diastolic function grade, AP-LAD Left atrial anteroposterior diameter, SI-LAD Left atrial suprainferior diameter, ML-LAD Left atrial mediolateral diameter, 2DLAVImax LA maximal volume measured by Biplane Simpson method index to BSA
Intraclass correlation coefficient for 3D STE derived parameters testing intraobserver and interobserver reproducibility under sinus or AF rhythm
| ICC | Interobserver variability | Intraobserver variability | ||
|---|---|---|---|---|
| Parameters | Sinus rhythm | AF rhythm | Sinus rhythm | AF rhythm |
| LAVmin(ml) | 0.950 (0.926 ~ 0.967) | 0.963 (0.921 ~ 0.982) | 0.994 (0.991 ~ 0.996) | 0.993 (0.986 ~ 0.997) |
| LAVmax(ml) | 0.964 (0.943 ~ 0.977) | 0.961 (0.919 ~ 0.981) | 0.993 (0.989 ~ 0.995) | 0.997 (0.994 ~ 0.999) |
| LAVpreA(ml) | 0.945 (0.918 ~ 0.964) | / | 0.978 (0.966 ~ 0.985) | / |
| LAVImax(ml/m2) | 0.962 (0.940 ~ 0.976) | 0.966 (0.929 ~ 0.984) | 0.993 (0.989 ~ 0.995) | 0.998 (0.995 ~ 0.999) |
| LAEV(ml) | 0.850 (0.781 ~ 0.899) | 0.799 (0.620 ~ 0.899) | 0.967 (0.950 ~ 0.978) | 0.903 (0.804 ~ 0.954) |
| LAEF(%) | 0.863 (0.799 ~ 0.908) | 0.657 (0.392 ~ 0.821) | 0.968 (0.951 ~ 0.979) | 0.855 (0.769 ~ 0.945) |
| LASr(%) | 0.818 (0.733 ~ 0.877) | 0.596 (0.305 ~ 0.785) | 0.877 (0.818 ~ 0.918) | 0.852 (0.708 ~ 0.929) |
| LAScd(%) | 0.664 (0.531 ~ 0.766) | 0.596 (0.305 ~ 0.785) | 0.643 (0.502 ~ 0.750) | 0.852 (0.708 ~ 0.929) |
| LASct(%) | 0.753 (0.647 ~ 0.831) | / | 0.861 (0.796 ~ 0.907) | / |
| LASrc(%) | 0.850 (0.780 ~ 0.972) | 0.705 (0.464 ~ 0.848) | 0.950 (0.925 ~ 0.967) | 0.908 (0.811 ~ 0.956) |
| LAScdc(%) | 0.639 (0.498 ~ 0.747) | 0.705 (0.464 ~ 0.848) | 0.710 (0.589 ~ 0.800) | 0.908 (0.811 ~ 0.956) |
| LASctc(%) | 0.814 (0.730 ~ 0.874) | / | 0.915 (0.873 ~ 0.971) | / |
LAVmin Minimal LA volume, LAVmax Maximal LA volume, LAVpreA LA volume at the onset of atrial contraction, LAVImax Maximal LA volume index to BSA, LAEV LA emptying volume, LAEF LA emptying fraction, pLAEF Passive LA emptying fraction, aLAEF Active LA emptying fraction, LASr Peak atrial longitudinal strain, LAScd Early diastolic longitudinal strain, LASct Late diastolic longitudinal strain, LASrc Peak atrial circumferential strain, LAScdc Early diastolic circumferential strain, LASctc Late diastolic circumferential strain
All p value < 0.001
Changes of 3D STE derived LA function parameters in PAF and Per-AF
| Parameters | Control | PAF | Per-AF | |
|---|---|---|---|---|
| LAVmin(ml) | 19 (16,24.5) | 30 (24,36)* | 62 (46,77)*† | <0.001 |
| LAVmax(ml) | 41 (35,50) | 52 (44,63)* | 78 (62,98)*† | <0.001 |
| LAVpreA(ml) | 33 (26,38) | 41 (36,50)* | / | <0.001 |
| LAVImax(ml/m2) | 24.9 (19.8,28.9) | 29.5 (24.9,35.9)* | 43.9 (34.9,54.8)*† | <0.001 |
| LAEV(ml) | 21 (17,26) | 21 (16,27) | 18 (13,21)*† | <0.001 |
| LAEF(%) | 53 (48,58) | 42 (35,48)* | 22 (18,25)*† | <0.001 |
| pLAEF(%) | 23 (19,28) | 20 (14,24)* | 22 (18,25)† | 0.003 |
| aLAEF(%) | 39 (34,44) | 27 (20,36)* | / | <0.001 |
| LASr(%) | 21 (17,26) | 16 (12,20)* | 7 (6,9)*† | <0.001 |
| LAScd(%) | −10(−12,−7) | −8(−10,−6)* | −7(−9,−6)* | <0.001 |
| LASct(%) | −11(−14,−9) | − 7(− 10,−4)* | / | <0.001 |
| LASrc(%) | 31 (26,36) | 18 (13,24)* | 8 (6,10)*† | <0.001 |
| LAScdc(%) | −11(− 14,−6) | − 7(− 10,−5)* | −8(− 10,−6)* | <0.001 |
| LASctc(%) | −20(−24,−15) | − 11(− 17,−7)* | / | <0.001 |
*p after Bonferroni’s correction < 0.05 versus control group
†p after Bonferroni’s correction < 0.05 versus PAF group
Multi-linear regression of AF type and 3D STE derived LA parameters
| Parameters | PAF( | Per-AF( | ||
|---|---|---|---|---|
| Partial regression Coefficient(β) | Adjusted p | Partial regression Coefficient(β) | Adjusted | |
| LAVmin(ml) | 9.15 (3.33 ~ 14.97) | 0.002 | 37.50 (29.57 ~ 45.43) | <0.001 |
| LAVmax(ml) | 6.81(−0.005 ~ 13.63) | 0.050 | 32.43 (22.78 ~ 42.08) | <0.001 |
| LAVpreA(ml) | 3.63 (0.39 ~ 6.86) | 0.028 | / | / |
| LAVImax(ml/m2) | 4.05 (0.01 ~ 8.10) | 0.050 | 19.85 (14.04 ~ 25.66) | <0.001 |
| LAEV(ml) | −0.93 (−2.84 ~ 0.98) | 0.337 | −1.72 (−4.08 ~ 0.65) | 0.154 |
| LAEF(%) | −9.49 (−11.91 ~ −7.06) | <0.001 | −25.99 (− 29.59 ~ − 22.39) | <0.001 |
| pLAEF(%) | − 1.79 (−3.71 ~ 0.12) | 0.066 | 1.95 (− 0.90 ~ 4.80) | 0.179 |
| aLAEF(%) | −8.43(− 11.51 ~ −5.35) | <0.001 | / | / |
| LASr(%) | −4.33 (−5.88 ~ −2.80) | <0.001 | −11.46 (− 13.71 ~ − 9.21) | <0.001 |
| LAScd(%) | 0.57 (−0.53 ~ 1.67) | 0.307 | 0.13 (−1.25 ~ 1.52) | 0.852 |
| LASct(%) | 2.45 (1.03 ~ 3.87) | 0.001 | / | / |
| LASrc(%) | −10.68 (−12.83 ~ −8.54) | <0.001 | − 18.90 (−22.08 ~ − 15.72) | <0.001 |
| LAScdc(%) | 2.27 (1.02 ~ 3.53) | <0.001 | 0.38 (−1.21 ~ 1.97) | 0.635 |
| LASctc(%) | 6.91 (4.45 ~ 9.38) | <0.001 | / | / |
adjusted p: p value after adjusted for age, BMI, HR, DBP, LVEF, E/e’, LV diastolic function grade, presence of CHF, hypertension, T2DM, CAD, stroke, use of antiarrhythmic medication, etc.
3D STE derived LA function parameters in subjects with normal LA size (defined as 2DLAVImax ≤34 ml/m2)
| Parameters | Control | PAF | Per-AF | |
|---|---|---|---|---|
| LAVmin(ml) | 19 (15,24) | 28 (22,34)* | 45 (40,48)*† | <0.001 |
| LAVmax(ml) | 41 (34,49) | 49 (43,57)* | 61 (54,66)*† | <0.001 |
| LAVpreA(ml) | 31 (26,37) | 39 (34,46)* | / | <0.001 |
| LAVImax(ml/m2) | 24.7 (19.7,27.8) | 28.1 (23.7,31.5)* | 31.6 (27.2,36.1)*† | <0.001 |
| LAEV(ml) | 21 (17,25) | 21 (16,26) | 16 (11,18)*† | <0.001 |
| LAEF(%) | 54 (48,58) | 43 (37,49)* | 24 (19,29)*† | <0.001 |
| pLAEF(%) | 24 (20,28) | 20 (15,24)* | 24 (19,29)† | <0.001 |
| aLAEF(%) | 40 (35,44) | 27 (21,36)* | / | <0.001 |
| LASr(%) | 21 (18,26) | 16 (13,20)* | 8 (6,11)*† | <0.001 |
| LAScd(%) | −10(−13,−7) | −8(−10,−6)* | −8(−11,−6)* | 0.007 |
| LASct(%) | −11(−14,−9) | −7(− 10,−4)* | / | <0.001 |
| LASrc(%) | 31 (26,36) | 19 (14,25)* | 8 (6,11)*† | <0.001 |
| LAScdc(%) | −11(− 14,−7) | −7(− 11,−5)* | −8(− 11,−6)* | <0.001 |
| LASctc(%) | −20(−24,−15) | −12(−18,−7)* | / | <0.001 |
*p after Bonferroni’s correction < 0.05 versus control group
†p after Bonferroni’s correction < 0.05 versus PAF group
Correlations between LA volumetric function parameters and strains indicating the same function
| LA function | Parameters | r with | r with | r with | |
|---|---|---|---|---|---|
| LAEF ( | pLAEF ( | aLAEF ( | |||
| Reservoir | LASr | 0.891* | / | / | <0.001 |
| LASrc | 0.947* | ||||
| Conduit | LAScd | −0.671† | / | <0.001 | |
| LAScdc | −0.884† | ||||
| Pump | LASct | −0.768✦ | <0.001 | ||
| LASctc | −0.914✦ |
r Correlation coefficient
Correlation coefficients marked with the same symbols (*/†/✦) suggest significant difference between their comparison
ROC analysis for differentiating PAF patients from non-AF subjects with 3D STE derived parameters
| Parameters | AUC(95%CI) | Cutoff value | Sensitivity(95%CI) | Specificity(95%CI) |
|---|---|---|---|---|
| LAVImax(ml/m2) | 0.703 (0.627 ~ 0.780) | 27.8 | 61.9 (53.3 ~ 70.0) | 72.9 (59.7 ~ 83.6) |
| LAVmin(ml) | 0.823 (0.762 ~ 0.884) | 21 | 86.3 (79.5 ~ 91.6) | 67.8 (54.4 ~ 79.4) |
| LAEF(%) | 0.830 (0.770 ~ 0.891) | 46.5 | 69.8 (61.4 ~ 77.3) | 84.7 (73.0 ~ 92.8) |
| pLAEF(%) | 0.639 (0.551 ~ 0.726) | 22.3 | 69.1 (60.7 ~ 76.6) | 57.6 (44.1 ~ 70.4) |
| aLAEF(%) | 0.826 (0.768 ~ 0.884) | 33.7 | 69.1 (60.7 ~ 76.6) | 79.7 (67.2 ~ 89.0) |
| LASr(%) | 0.758 (0.685 ~ 0.830) | 18 | 69.1 (60.7 ~ 76.6) | 72.9 (59.7 ~ 83.6) |
| LASrc(%) | 0.850 (0.793 ~ 0.908) | 24 | 75.5 (67.5 ~ 82.4) | 81.4 (69.1 ~ 90.3) |
| LAScd(%) | 0.635 (0.549 ~ 0.722) | −11 | 81.3 (73.8 ~ 87.4) | 42.4 (29.6 ~ 55.9) |
| LAScdc(%) | 0.687 (0.602 ~ 0.772) | −9 | 65.5 (56.9 ~ 73.3) | 69.5 (56.1 ~ 80.8) |
| LASct(%) | 0.741 (0.669 ~ 0.814) | −8.5 | 59.7 (51.1 ~ 67.9) | 79.7 (67.2 ~ 89.0) |
| LASctc(%) | 0.828 (0.768 ~ 0.887) | −14 | 62.6 (54.0 ~ 70.6) | 86.4 (75.0 ~ 94.0) |
AUC Area under the curve, 95%CI 95% confidence interval
All p < 0.001
PPV and NPV of LA parameters when applied to populations with AF prevalence of 1% or 20%
| Parameters | Prevalence 1% | Prevalence 20% | ||
|---|---|---|---|---|
| PPV(95%CI) | NPV(95%CI) | PPV(95%CI) | NPV(95%CI) | |
| LAVImax(ml/m2) | 2.3 (1.5 ~ 3.4) | 99.5 (99.3 ~ 99.6) | 36.3 (29.7 ~ 43.6) | 88.4 (85.8 ~ 90.6) |
| LAVmin(ml) | 2.6 (1.8 ~ 3.8) | 99.8 (99.7 ~ 99.9) | 40.1 (34.3 ~ 46.2) | 95.2 (92.8 ~ 96.8) |
| LAEF(%) | 4.4 (2.4 ~ 7.8) | 99.6 (99.5 ~ 99.7) | 53.3 (43.2 ~ 63.1) | 91.8 (89.6 ~ 93.6) |
| aLAEF(%) | 3.3 (2.0 ~ 5.4) | 99.6 (99.5 ~ 99.7) | 46.0 (37.5 ~ 54.6) | 91.2 (88.8 ~ 93.1) |
| LASrc(%) | 3.9 (2.3 ~ 6.6) | 99.7 (99.6 ~ 99.8) | 50.4 (41.4 ~ 59.3) | 93.0 (90.8 ~ 94.7) |
| LAStc(%) | 4.5 (2.4 ~ 8.3) | 99.6 (99.4 ~ 99.7) | 53.5 (42.6 ~ 64.1) | 90.2 (88.1 ~ 92.0) |
PPV Positive predictive value, NPV Negative predictive value